View in EDS PDF Full Text

Molecular remission of chronic myeloid leukaemia in a patient with hepatitis and a second kidney transplant.

Saved in:
Bibliographic Details
Title: Molecular remission of chronic myeloid leukaemia in a patient with hepatitis and a second kidney transplant.
Authors: Castillo-Rama, M.1, Grande, C.2, Martínez-Sánchez, P.2, Olavarria, E.3, Marín, D.3, Paz-Artal, E.1, Andrés, A.4, Morales, J. M.4 josemariamoralesc@yahoo.es
Source: Nefrologia. Dec2009, Vol. 29 Issue 6, p604-607. 4p. 3 Charts, 2 Graphs.
Subjects: CHRONIC myeloid leukemia, HEPATITIS, KIDNEY transplant patients, ONCOGENES, PROTEIN-tyrosine kinases, DISEASE remission, HEPATITIS C, CARDIOVASCULAR agents, PATIENTS
Abstract (English): Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by clonal expansion of cells in the myeloid line, expressing the BCRABL fusion protein responsible for the oncogenic effect of CML. The current frontline therapy in CML is the BCR-ABL tyrosine kinase inhibitor, Imatinib. Although this drug has been shown to improve survival in CML patients, its role in the context of a transplant setting has not been widely described in the literature. We report on the long term molecular remission of CML in a 55 year old man with a second renal transplant who is hepatitis C virus positive, and has associated cardiovascular and immunological risk factors. [ABSTRACT FROM AUTHOR]
Abstract (Spanish): La leucemia mieloide crónica (LMC) es una enfermedad mieloproliferativa caracterizada por la expansión clonal de células mieloides que expresan la proteína de fusión BCR-ABL, responsable de los efectos oncogénicos de la LMC. La terapia actual en el tratamiento de LMC es el inhibidor de la BCR-ABL tirosín-kinasa, imatinib. Aunque este fármaco ha demostrado mejorar la supervivencia en pacientes con LMC, su papel en el contexto del trasplante renal no ha sido ampliamente descrito en la literatura. Presentamos un caso de remisión molecular de LMC en un varón de 55 años con un segundo trasplante renal, hepatitis C y con riesgos cardiovasculares e inmunológicos asociados. [ABSTRACT FROM AUTHOR]
Copyright of Nefrologia is the property of Revista Nefrologia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: MedicLatina
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: lth
DbLabel: MedicLatina
An: 47253486
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Molecular remission of chronic myeloid leukaemia in a patient with hepatitis and a second kidney transplant.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Castillo-Rama%2C+M%2E%22">Castillo-Rama, M.</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Grande%2C+C%2E%22">Grande, C.</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Martínez-Sánchez%2C+P%2E%22">Martínez-Sánchez, P.</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Olavarria%2C+E%2E%22">Olavarria, E.</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22Marín%2C+D%2E%22">Marín, D.</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22Paz-Artal%2C+E%2E%22">Paz-Artal, E.</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Andrés%2C+A%2E%22">Andrés, A.</searchLink><relatesTo>4</relatesTo><br /><searchLink fieldCode="AR" term="%22Morales%2C+J%2E+M%2E%22">Morales, J. M.</searchLink><relatesTo>4</relatesTo><i> josemariamoralesc@yahoo.es</i>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Nefrologia%22">Nefrologia</searchLink>. Dec2009, Vol. 29 Issue 6, p604-607. 4p. 3 Charts, 2 Graphs.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22CHRONIC+myeloid+leukemia%22">CHRONIC myeloid leukemia</searchLink><br /><searchLink fieldCode="DE" term="%22HEPATITIS%22">HEPATITIS</searchLink><br /><searchLink fieldCode="DE" term="%22KIDNEY+transplant+patients%22">KIDNEY transplant patients</searchLink><br /><searchLink fieldCode="DE" term="%22ONCOGENES%22">ONCOGENES</searchLink><br /><searchLink fieldCode="DE" term="%22PROTEIN-tyrosine+kinases%22">PROTEIN-tyrosine kinases</searchLink><br /><searchLink fieldCode="DE" term="%22DISEASE+remission%22">DISEASE remission</searchLink><br /><searchLink fieldCode="DE" term="%22HEPATITIS+C%22">HEPATITIS C</searchLink><br /><searchLink fieldCode="DE" term="%22CARDIOVASCULAR+agents%22">CARDIOVASCULAR agents</searchLink><br /><searchLink fieldCode="DE" term="%22PATIENTS%22">PATIENTS</searchLink>
– Name: Abstract
  Label: Abstract (English)
  Group: Ab
  Data: Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by clonal expansion of cells in the myeloid line, expressing the BCRABL fusion protein responsible for the oncogenic effect of CML. The current frontline therapy in CML is the BCR-ABL tyrosine kinase inhibitor, Imatinib. Although this drug has been shown to improve survival in CML patients, its role in the context of a transplant setting has not been widely described in the literature. We report on the long term molecular remission of CML in a 55 year old man with a second renal transplant who is hepatitis C virus positive, and has associated cardiovascular and immunological risk factors. [ABSTRACT FROM AUTHOR]
– Name: Abstract
  Label: Abstract (Spanish)
  Group: Ab
  Data: La leucemia mieloide crónica (LMC) es una enfermedad mieloproliferativa caracterizada por la expansión clonal de células mieloides que expresan la proteína de fusión BCR-ABL, responsable de los efectos oncogénicos de la LMC. La terapia actual en el tratamiento de LMC es el inhibidor de la BCR-ABL tirosín-kinasa, imatinib. Aunque este fármaco ha demostrado mejorar la supervivencia en pacientes con LMC, su papel en el contexto del trasplante renal no ha sido ampliamente descrito en la literatura. Presentamos un caso de remisión molecular de LMC en un varón de 55 años con un segundo trasplante renal, hepatitis C y con riesgos cardiovasculares e inmunológicos asociados. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Nefrologia is the property of Revista Nefrologia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=47253486
RecordInfo BibRecord:
  BibEntity:
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 4
        StartPage: 604
    Subjects:
      – SubjectFull: CHRONIC myeloid leukemia
        Type: general
      – SubjectFull: HEPATITIS
        Type: general
      – SubjectFull: KIDNEY transplant patients
        Type: general
      – SubjectFull: ONCOGENES
        Type: general
      – SubjectFull: PROTEIN-tyrosine kinases
        Type: general
      – SubjectFull: DISEASE remission
        Type: general
      – SubjectFull: HEPATITIS C
        Type: general
      – SubjectFull: CARDIOVASCULAR agents
        Type: general
      – SubjectFull: PATIENTS
        Type: general
    Titles:
      – TitleFull: Molecular remission of chronic myeloid leukaemia in a patient with hepatitis and a second kidney transplant.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Castillo-Rama, M.
      – PersonEntity:
          Name:
            NameFull: Grande, C.
      – PersonEntity:
          Name:
            NameFull: Martínez-Sánchez, P.
      – PersonEntity:
          Name:
            NameFull: Olavarria, E.
      – PersonEntity:
          Name:
            NameFull: Marín, D.
      – PersonEntity:
          Name:
            NameFull: Paz-Artal, E.
      – PersonEntity:
          Name:
            NameFull: Andrés, A.
      – PersonEntity:
          Name:
            NameFull: Morales, J. M.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: Dec2009
              Type: published
              Y: 2009
          Identifiers:
            – Type: issn-print
              Value: 02116995
          Numbering:
            – Type: volume
              Value: 29
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Nefrologia
              Type: main
ResultId 1